Claims for Patent: 12,146,889

Summary for Patent: 12,146,889

Title:	Compounds and combinations thereof for treating neurological and psychiatric conditions
Abstract:	This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US18/494,550
Patent Claims:	1. A method of treating major depressive disorder, comprising screening a human patient who is experiencing major depressive disorder to determine if the human patient is receiving any other medications that contain bupropion; and if the human patient is receiving a medication containing bupropion, and concomitant use of the other medication containing bupropion and a tablet containing 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride is clinically warranted, then: administering the tablet to the human patient once daily in the morning for 3 days, and after 3 days, administering the tablet to the human patient twice daily at least 8 hours apart, and instructing the patient to not crush, divide or chew the tablet, and continuing the concomitant use of the other medication containing bupropion; monitoring the human patient for a neuropsychiatric reaction, and instructing the human patient to contact a healthcare provider if a neuropsychiatric reaction occurs; and informing the patient of a dose-related risk of seizure associated with bupropion-containing products and immediately discontinuing administration of the tablet if the human patient experiences a seizure. 2. The method of claim 1, further comprising assessing the blood pressure of the human patient and monitoring the blood pressure periodically during treatment. 3. The method of claim 1, further comprising screening the human patient for a personal or family history of bipolar disorder, mania, or hypomania. 4. The method of claim 1, wherein the tablet contains an immediate-release formulation of dextromethorphan hydrobromide. 5. The method of claim 4, wherein the tablet contains an extended-release formulation of bupropion hydrochloride. 6. A method of treating major depressive disorder, comprising screening a human patient who is experiencing major depressive disorder to determine if the human patient is receiving any other medications that contain dextromethorphan; and if the human patient is receiving a medication containing dextromethorphan, and concomitant use of the other medication containing dextromethorphan and a tablet containing 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride is clinically warranted, then: administering the tablet to the human patient once daily in the morning for 3 days, and after 3 days, administering the tablet to the human patient twice daily at least 8 hours apart, instructing the patient to not crush, divide or chew the tablet, and continuing the concomitant use of the other medication containing dextromethorphan; informing the human patient of the increased risk for serotonin syndrome, and if the human patient experiences a symptom of serotonin syndrome, immediately discontinuing administration of the tablet, the medication containing dextromethorphan, or both, and initiating supportive symptomatic treatment for the symptom of serotonin syndrome; and monitoring the human patient for a neuropsychiatric reaction, and instructing the human patient to contact a healthcare provider if a neuropsychiatric reaction occurs. 7. The method of claim 6, further comprising assessing the blood pressure of the human patient and monitoring the blood pressure periodically during treatment. 8. The method of claim 6, further comprising screening the human patient for a personal or family history of bipolar disorder, mania, or hypomania. 9. The method of claim 6, wherein the tablet contains an immediate-release formulation of dextromethorphan hydrobromide. 10. The method of claim 9, wherein the tablet contains an extended-release formulation of bupropion hydrochloride. 11. A method of treating major depressive disorder, comprising screening a human patient who is experiencing major depressive disorder to determine if the human patient is receiving a serotonergic drug; and if the patient is a receiving a serotonergic drug and concomitant use of the serotonergic drug, and a tablet containing 45 mg of dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride is clinically warranted, then: administering the tablet to the human patient once daily in the morning for 3 days, and after 3 days, administering the tablet to the human patient twice daily at least 8 hours apart, instructing the patient to not crush, divide or chew the tablet, and continuing the concomitant use of the serotonergic drug; and informing the human patient of the increased risk for serotonin syndrome, and, if the human patient experiences a symptom of serotonin syndrome, immediately discontinuing administration of the tablet, the serotonergic drug, or both, and initiating supportive symptomatic treatment for the symptom of serotonin syndrome. 12. The method of claim 11, further comprising assessing the blood pressure of the human patient and monitoring the blood pressure periodically during treatment. 13. The method of claim 11, further comprising screening the human patient for a personal or family history of bipolar disorder, mania, or hypomania. 14. The method of claim 11, wherein the tablet contains an immediate-release formulation of dextromethorphan hydrobromide. 15. The method of claim 14, wherein the tablet contains an extended-release formulation of bupropion hydrochloride. 16. The method of claim 11, further comprising monitoring the human patient for a neuropsychiatric reaction, and instructing the human patient to contact a healthcare provider if a neuropsychiatric reaction occurs.